Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 684 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Crohn Disease Clear all
Completed Phase 2 Interventional Results available

A Study To Monitor Long-Term Treatment With PF-00547659

NCT01298492
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-00547659
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
47
States / cities
La Jolla, California • Orange, California • Lafayette, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

NCT00055536
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Not applicable Interventional Results available

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

NCT00791557
View directory record Official record
Conditions
Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
39
States / cities
Birmingham, Alabama • Mobile, Alabama • Boulder, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 26, 2026, 10:37 AM EDT
Not listed Not applicable Interventional

Using Virtual Reality for Patients With Gastrointestinal Disease

NCT03719209
View directory record Official record
Conditions
Gastrointestinal Disease, Inflammatory Bowel Diseases
Interventions
HealthVoyager, Standard Practice
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 26, 2026, 10:37 AM EDT
Not yet recruiting Phase 1 Interventional

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

NCT05852587
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridioides Difficile Infection
Interventions
Xylitol, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Results available

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
190
States / cities
Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 26, 2026, 10:37 AM EDT
Terminated No phase listed Observational

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

NCT01582568
View directory record Official record
Conditions
Crohns Disease
Interventions
Certolizumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 26, 2026, 10:37 AM EDT
Not yet recruiting Not applicable Interventional

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

NCT07017959
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
LpD3.5 supplementation., Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

NCT05078879
View directory record Official record
Conditions
Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
Interventions
Empagliflozin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

NCT03345849
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib, Placebo for Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 26, 2026, 10:37 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536
View directory record Official record
Conditions
Crohn's Disease
Interventions
brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Escondido, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Recruiting Phase 3 Interventional

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
Vedolizumab IV
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Active, not recruiting Phase 3 Interventional

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06408935
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab
Drug
Lead sponsor
Janssen-Cilag Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Recruiting No phase listed Observational

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

NCT02103361
View directory record Official record
Conditions
Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions
Ustekinumab, Guselkumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 26, 2026, 10:37 AM EDT
Completed No phase listed Observational

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

NCT00819663
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

NCT00106314
View directory record Official record
Conditions
Crohn's Disease
Interventions
Dehydroepiandrosterone [DHEA]
Drug
Lead sponsor
Inflabloc Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Huntsville, Alabama • Anaheim, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2007 · Synced Oct 26, 2026, 10:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Combinatorial Single Cell Strategies for a Crohn's Disease Gut Cell Atlas

NCT04113733
View directory record Official record
Conditions
Crohn Disease
Interventions
Sample Collection
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 26, 2026, 10:37 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease

NCT05075811
View directory record Official record
Conditions
Pouch, Ileal, Fistula
Interventions
Ossium vBM-MSC, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 10:37 AM EDT
Not listed Phase 4 Interventional

Optimizing Cimzia in Crohn's Patients

NCT01024647
View directory record Official record
Conditions
Crohn's Disease
Interventions
certolizumab pegol
Biological
Lead sponsor
Atlanta Gastroenterology Associates
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 26, 2026, 10:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study With Pentasa in Patients With Active Crohn's Disease

NCT00862121
View directory record Official record
Conditions
Crohn´s Disease
Interventions
Pentasa, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
San Diego, California • Clearwater, Florida • John's Creek, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 26, 2026, 10:37 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 26, 2026, 10:37 AM EDT
Enrolling by invitation Not applicable Interventional

Utility of Random Biopsies in Patients With Inflammatory Bowel Disease

NCT06560021
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Biopsy strategy
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
1,642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 26, 2026, 10:37 AM EDT